We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$4.59B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+37.76%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.89B
AUM Growth
+$717M
(+17%)
Cap. Flow
-$266M
Cap. Flow
% of AUM
-5.43%
Top 10 Holdings %
Top 10 Hldgs %
40.48%
Holding
126
New
22
Increased
22
Reduced
35
Closed
16
Top Buys
| 1 |
Pfizer
PFE
|
+$41.7M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$37.3M |
| 3 |
Elevance Health
ELV
|
+$33.5M |
| 4 |
HELP
Cybin Inc
HELP
|
+$24.7M |
| 5 |
Bruker
BRKR
|
+$23.5M |
Top Sells
| 1 |
TERN
Terns Pharmaceuticals
TERN
|
+$125M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$65.8M |
| 3 |
EXAS
Exact Sciences
EXAS
|
+$51.6M |
| 4 |
Axsome Therapeutics
AXSM
|
+$38.9M |
| 5 |
SI-BONE Inc
SIBN
|
+$38M |
Sector Composition
| 1 | Healthcare | 99.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RAPT
26
DELISTED
RAPT Therapeutics
RAPT
| $55.6M | 1.14% |
1,642,891
+556,273
| +51% | +$17.3M |
|
27
Corvus Pharmaceuticals
CRVS
$1.26B
| $55.2M | 1.13% |
7,165,006
| – | – |
|
28
United Therapeutics
UTHR
$22.6B
| $51.3M | 1.05% |
105,200
-9,700
| -8% | -$4.52M |
|
|
ABVX
29
Abivax
ABVX
$11.8B
| $49.6M | 1.02% |
367,900
-12,100
| -3% | -$1.32M |
|
30
Roivant Sciences
ROIV
$25.1B
| $47.5M | 0.97% |
2,190,907
-523,891
| -19% | -$10.3M |
|
31
Crinetics Pharmaceuticals
CRNX
$8.88B
| $46.5M | 0.95% |
999,000
-100,000
| -9% | -$4.45M |
|
|
32
Axsome Therapeutics
AXSM
$12.1B
| $46.2M | 0.95% |
253,121
-278,679
| -52% | -$38.9M |
|
33
EyePoint Inc
EYPT
$1.13B
| $45.1M | 0.92% |
2,468,314
+672,314
| +37% | +$9.53M |
|
|
RNAM
34
DELISTED
Avidity Biosciences
RNAM
| $44.7M | 0.91% |
619,530
-1,019,356
| -62% | -$65.8M |
|
35
Neurocrine Biosciences
NBIX
$17.2B
| $44.6M | 0.91% |
314,240
-39,400
| -11% | -$5.71M |
|
36
Dyne Therapeutics
DYN
$3.86B
| $43.1M | 0.88% |
2,202,184
-112,000
| -5% | -$2.12M |
|
|
37
Bristol-Myers Squibb
BMY
$119B
| $41.8M | 0.86% |
+775,000
| New | +$37.3M |
|
|
38
Pfizer
PFE
$141B
| $41.2M | 0.84% |
+1,652,900
| New | +$41.7M |
|
39
Trevi Therapeutics
TRVI
$2.49B
| $39.9M | 0.82% |
3,190,700
-117,700
| -4% | -$1.36M |
|
40
Neuropace
NPCE
$554M
| $37.2M | 0.76% |
2,406,335
-207,849
| -8% | -$2.78M |
|
41
Ascendis Pharma A/S
ASND
$17.4B
| $36.7M | 0.75% |
171,977
-19,928
| -10% | -$4.12M |
|
|
EXAS
42
DELISTED
Exact Sciences
EXAS
| $35.7M | 0.73% |
351,716
-642,900
| -65% | -$51.6M |
|
43
Mineralys Therapeutics
MLYS
$2.37B
| $35.6M | 0.73% |
980,400
-489,094
| -33% | -$19.6M |
|
|
44
Elevance Health
ELV
$84.5B
| $34.7M | 0.71% |
+99,100
| New | +$33.5M |
|
45
Forte Biosciences
FBRX
$889M
| $32.6M | 0.67% |
1,196,955
| – | – |
|
46
Prelude Therapeutics
PRLD
$354M
| $31.6M | 0.65% |
10,909,256
| – | – |
|
|
HELP
47
Cybin Inc
HELP
$410M
| $31.4M | 0.64% |
+3,840,500
| New | +$24.7M |
|
48
Oric Pharmaceuticals
ORIC
$1.14B
| $29.8M | 0.61% |
3,641,756
| – | – |
|
49
Krystal Biotech
KRYS
$10.2B
| $29.5M | 0.6% |
119,800
+17,055
| +17% | +$3.59M |
|
50
Praxis Precision Medicines
PRAX
$8.84B
| $27.9M | 0.57% |
+94,500
| New | +$17.6M |
|
Similar funds
CGI
LNWTC
SCM
AG
SCM
SV
ANTB
ECM